Influence of TCF7L2 gene variants on the therapeutic response to the dipeptidylpeptidase-4 inhibitor linagliptin

Diabetologia

Volumn 57, Issue 9, 2014, Pages 1869-1875

  Zimdahl, Heike ^a   Ittrich, Carina ^a   Graefe Mody, Ulrike ^a   Boehm, Bernhard O ^b,c,d   Mark, Michael ^a   Woerle, Hans Juergen ^a   Dugi, Klaus A ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^b NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Clinical science; DPP 4 inhibitor; Genetics of type 2 diabetes; Human; Linagliptin; Oral pharmacological agents; Pharmacogenomics; TCF7L2

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; DNA; HEMOGLOBIN A1C; LINAGLIPTIN; METFORMIN; PIOGLITAZONE; PLACEBO; SULFONYLUREA; TRANSCRIPTION FACTOR 7 LIKE 2; PURINE DERIVATIVE; QUINAZOLINE DERIVATIVE; TCF7L2 PROTEIN, HUMAN; GLUCOSE;

ADULT; AGED; ALLELE; ARTICLE; BLOOD; CONTROLLED STUDY; FEMALE; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; GLUCOSE BLOOD LEVEL; HETEROZYGOSITY; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET CELL; PHARMACOGENOMICS; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TREATMENT RESPONSE; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; GENETIC PREDISPOSITION; GENETICS; PHASE 3 CLINICAL TRIAL; BLOOD SAMPLING; CLINICAL STUDY; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; GENE; GENE FREQUENCY; GLYCEMIC CONTROL; HOMOZYGOTE; MONOTHERAPY; PROCEDURES; RISK FACTOR;

ALLELES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PURINES; QUINAZOLINES; TRANSCRIPTION FACTOR 7-LIKE 2 PROTEIN;

EID: 84905569407     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-014-3276-y     Document Type: Article

References (28)

1. International Diabetes Federation (2011) IDF diabetes atlas. Available from www.idf.org/diabetesatlas, accessed 4 September 2012
2. Dupuis J, Langenberg C, Prokopenko I, et al. (2010) New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet 42:105-116
3. Frayling TM (2007) Genome-wide association studies provide new insights into type 2 diabetes aetiology. Nat Rev Genet 8:657-662
4. Voight BF, Scott LJ, Steinthorsdottir V, et al. (2010) Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet 42:579-589
5. Cauchi S, El Achhab Y, Choquet H, et al. (2007) TCF7L2 is reproducibly associated with type 2 diabetes in various ethnic groups: a global meta-analysis. J Mol Med (Berl) 85:777-782
6. Tong Y, Lin Y, Zhang Y, et al. (2009) Association between TCF7L2 gene polymorphisms and susceptibility to type 2 diabetes mellitus: a large Human Genome Epidemiology (HuGE) review and meta-analysis. BMC Med Genet 10:15
7. Grant SFA, Thorleifsson G, Reynisdottir I, et al. (2006) Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 38:320-323
8. Helgason A, Palsson S, Thorleifsson G, et al. (2007) Refining the impact of TCF7L2 gene variants on type 2 diabetes and adaptive evolution. Nat Genet 39:218-225
9. Pearson ER, Donnelly LA, Kimber C, et al. (2007) Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study. Diabetes 56:2178-2182
10. Lyssenko V, Lupi R, Marchetti P, et al. (2007) Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J Clin Invest 117:2155-2163
11. Pilgaard K, Jensen CB, Schou JH, et al. (2009) The T allele of rs7903146 TCF7L2 is associated with impaired insulinotropic action of incretin hormones, reduced 24 h profiles of plasma insulin and glucagon, and increased hepatic glucose production in young healthy men. Diabetologia 52:1298-1307
12. Shu L, Matveyenko AV, Kerr-Conte J, Cho JH, McIntosh CH, Maedler K (2009) Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP- and GLP-1 receptors and impaired beta-cell function. Hum Mol Genet 18:2388-2399
13. Shu L, Sauter NS, Schulthess FT, Matveyenko AV, Oberholzer J, Maedler K (2008) Transcription factor 7-like 2 regulates beta-cell survival and function in human pancreatic islets. Diabetes 57:645-653
14. Woerle HJ, Carneiro L, Derani A, Goke B, Schirra J (2012) The role of endogenous incretin secretion as amplifier of glucose-stimulated insulin secretion in healthy subjects and patients with type 2 diabetes. Diabetes 61:2349-2358
15. Drucker DJ, Nauck MA (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368:1696-1705
16. Forst T, Uhlig-Laske B, Ring A, Ritzhaupt A, Graefe-Mody U, Dugi KA (2011) The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus. Diabetes Obes Metab 13:542-550
17. Deacon CF, Holst JJ (2010) Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes. Expert Opin Investig Drugs 19:133-140
18. Taskinen MR, Rosenstock J, Tamminen I, et al. (2011) Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 13:65-74
19. Owens DR, Swallow R, Dugi KA, Woerle HJ (2011) Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study. Diabet Med 28:1352-1361
20. Del Prato S, Barnett AH, Huisman H, Neubacher D, Woerle HJ, Dugi KA (2011) Effect of linagliptin monotherapy on glycaemic control and markers of beta-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab 13:258-267
21. Gomis R, Espadero RM, Jones R, Woerle HJ, Dugi KA (2011) Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 13:653-661
22. Sanger F, Nicklen S, Coulson AR (1977) DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A 74:5463-5467
23. National Center for Biotechnology Information (2012) Database of single nucleotide polymorphisms (dbSNP). National Library of Medicine, Bethesda
24. Sherry ST, Ward MH, Kholodov M, et al. (2001) dbSNP: the NCBI database of genetic variation. Nucleic Acids Res 29:308-311
25. Jin T (2008) The WNT signalling pathway and diabetes mellitus. Diabetologia 51:1771-1780
26. Jin T, Liu L (2008) The Wnt signaling pathway effector TCF7L2 and type 2 diabetes mellitus. Mol Endocrinol 22:2383-2392
27. Yi F, Sun J, Lim GE, Fantus IG, Brubaker PL, Jin T (2008) Cross talk between the insulin and Wnt signaling pathways: evidence from intestinal endocrine L cells. Endocrinology 149:2341-2351
28. Schäfer SA, Tschritter O, Machicao F, et al. (2007) Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms. Diabetologia 50:2443-2450